BioLargo, Inc.
BLGO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -4.98 | -1.53 | -0.16 |
| FCF Yield | -5.27% | -3.39% | -2.20% | -3.30% |
| EV / EBITDA | -7.64 | -36.39 | -46.60 | -36.57 |
| Quality | ||||
| ROIC | -109.14% | -18.52% | -22.87% | -18.77% |
| Gross Margin | 33.73% | 51.17% | 45.52% | 47.85% |
| Cash Conversion Ratio | 0.38 | 1.13 | 0.95 | 1.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.76% | 16.95% | 23.43% | 44.56% |
| Free Cash Flow Growth | -30.26% | -15.74% | 3.23% | -13.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.47 | -0.11 | -0.27 | 0.65 |
| Interest Coverage | 44.78 | -22.53 | -28.65 | -12.72 |
| Efficiency | ||||
| Inventory Turnover | 1.79 | 3.05 | 4.83 | 5.78 |
| Cash Conversion Cycle | 112.45 | 93.74 | 58.40 | 42.90 |